BaltaSMikhailidisDPDemirkolS. Endocan—a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology. 2014;65(9):773–777.
2.
KaperonisEALiapisCDKakisisJDDimitroulisDPapavassiliouVG. Inflammation and atherosclerosis. Eur J Vasc Endovasc Surg. 2006;31(4):386–393.
3.
LaneHASmithJCDaviesJS. Noninvasive assessment of preclinical atherosclerosis. Vasc Health Risk Manag. 2006;2(1):19–30.
4.
WhayneTF. Endocan in hypertension and cardiovascular disease. Angiology. 2014;65(9):757–759.
5.
YilmazMISiriopolDSaglamM. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int. 2014;86(6):1213–1220.
6.
KaramanMBaltaSAySA. The comparative effects of valsartan and amlodipine on vWf levels and N/L ratio in patients with newly diagnosed hypertension. Clin Exp Hypertens. 2013;35(7):516–522.
7.
LeeWKuSKKimSWBaeJS. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol. 2014;229(5):620–630.
8.
SuY-HShuK-HHuC-P. Serum Endocan correlated with stage of chronic kidney disease and deterioration in renal transplant recipients. Transplant Proc. 2014;46(2):323–327.
9.
TokDEkizFBasarOCobanSOzturkG. Serum endocan levels in patients with chronic liver disease. Int J Clin Exp Med. 2014;7(7):1802–1807.
10.
BaltaIBaltaSKoryurekOM. Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol. 2014;70(2):291–296.
11.
BaltaIBaltaSDemirkolS. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol. 2013;169(5):1066–1070.
12.
FiciFCelikTBaltaS. Comparative effects of nebivolol and metoprolol on red cell distribution width and neutrophil/lymphocyte ratio in patients with newly diagnosed essential hypertension. J Cardiovasc Pharmacol. 2013;62(4):388–393.
